RedHill Biopharma
(NASDAQ: RDHL)
|
5:30 PM UTC, 07/03/24 | |||
---|---|---|---|---|
Last: $0.36 | Change: +0.00 | %Change: +0.17% | Volume: 236,986 |
Open: | $ 0.36 | Volume: | 236,986 | |
---|---|---|---|---|
High: | $ 0.37 | Yield(%) | 0.00 | |
Low: | $ 0.36 | P/E Ratio (ttm): | 0.10 | |
Dividend ($): | n/a | Market Cap ($): | 11.47M | |
EPS ($) | -3.16 | Shares Out: | 31.87M |
% Price Change (last 4 weeks): | -23.79 |
---|---|
% Price Change (last 13 weeks): | -31.70 |
% Price Change (last 26 weeks): | -75.21 |
% Price Change (last 52 weeks): | -69.58 |
% Price Change (year to date): | -75.34 |
Return on Equity (%): | n/a |
---|---|
Return on Assets (%): | 26.23 |
Return on Invested Capital (%): | -134.65 |
Gross Profit Margin (%): | 47.03 |
---|---|
Net Profit Margin (%): | 366.25 |
Operating Profit Margin (%): | -481.35 |
|
|
50-day Moving Average: | $0.43 |
---|---|
200-day Moving Average: | $0.66 |
Avg. Daily Vol. (last 50 days): | 262,782 |
Avg. Daily Vol. (last 200 days): | 3,820,182 |
52-wk high: | $3.28 |
52-wk low: | $0.26 |
Bid: | $0.36 |
Ask: | $0.36 |
RedHill Biopharma Ltd. develops medicines for gastrointestinal and infectious diseases. It operates through Commercial Operations, and the Research and Development segments. The Commercial Operations segment covers all areas relating to the commercial sales and is being performed by the subsidiary in the U.S. The Research and Development segment includes the study and licensing of therapeutic candidates. Its products include Talicia, Movantik, and Aemcolo. The company was founded by Dror Ben-Asher and Ori Shilo on August 3, 2009 and is headquartered in Tel Aviv, Israel.
|
RedHill Biopharma
21 Ha'arba'a Street Tel Aviv TA 6473921 Phone: 972.3.541.3131 Fax: 972.3.541.3144 http://www.redhillbio.com |
Earnings (1year) ($): | -3.16 |
---|---|
Annual Dividend ($): | 0.00 |
Current P/E Ratio (ttm): | 0.10 |
Book Value ($): | 0.11 |
Cash Flow ($): | 1.31 |
Price/Earnings (x): | 0.10 |
---|---|
Price/Sales (x): | 1.45 |
Price/Book (x): | 13.88 |
Price/Cash Flow (x): | n/a |
Quick Ratio (x): | 0.54 |
---|---|
Current Ratio (x): | 0.84 |
LT Debt/Equity (x): | 21.99 |
Total Debt/Equity (x): | 56.69 |